These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 36632846)
1. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846 [TBL] [Abstract][Full Text] [Related]
2. Predictive molecular pathology in metastatic thyroid cancer: the role of Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189 [TBL] [Abstract][Full Text] [Related]
3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500 [No Abstract] [Full Text] [Related]
4. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311 [TBL] [Abstract][Full Text] [Related]
5. Precision Targeted Therapy with BLU-667 for Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135 [TBL] [Abstract][Full Text] [Related]
6. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661 [TBL] [Abstract][Full Text] [Related]
7. Precision therapy for RET-altered cancers with RET inhibitors. Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699 [TBL] [Abstract][Full Text] [Related]
8. Targeting RET alterations in cancer: Recent progress and future directions. Shabbir A; Kojadinovic A; Shafiq T; Mundi PS Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304 [TBL] [Abstract][Full Text] [Related]
9. Precision oncology with selective RET inhibitor selpercatinib in Gouda MA; Subbiah V Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768 [TBL] [Abstract][Full Text] [Related]
10. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056 [TBL] [Abstract][Full Text] [Related]
11. RET fusions in solid tumors. Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421 [TBL] [Abstract][Full Text] [Related]
12. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors. Le D; Konda B Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380 [TBL] [Abstract][Full Text] [Related]
14. Precious Gene: The Application of RET-Altered Inhibitors. Gou Q; Gan X; Li L; Gou Q; Zhang T Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971 [TBL] [Abstract][Full Text] [Related]
15. Progress and challenges in RET-targeted cancer therapy. Hu X; Khatri U; Shen T; Wu J Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086 [TBL] [Abstract][Full Text] [Related]
16. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106 [TBL] [Abstract][Full Text] [Related]
17. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib. Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019 [TBL] [Abstract][Full Text] [Related]
18. [RET Gene Alterations in Thyroid Cancer-Towards Treatment with Selective RET Inhibitors]. Mitsutake N; Nakamura K; Suzuki S Gan To Kagaku Ryoho; 2023 May; 50(5):611-614. PubMed ID: 37218322 [TBL] [Abstract][Full Text] [Related]
19. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Roskoski R; Sadeghi-Nejad A Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153 [TBL] [Abstract][Full Text] [Related]
20. Targeting RET alterations in non-small cell lung cancer. Nishikawa G; Klein MA Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]